NovoNorm 2 mg, 30 tablets

Trade Name:

NovoNorm

Composition

Each tablet contains:

Repaglinide 2 mg

Inactive ingredients:

Poloxamer, povidone, meglumine, corn starch, anhydrous calcium hydrogen phosphate, microcrystalline cellulose (E460), glycerol 85% (glycerol), potassium polacrilin (potassium polyacrylate), magnesium stearate, iron oxide red (E172).

Properties

Oral hypoglycemic agent. Rapidly lowers blood glucose levels by stimulating the release of insulin from functioning pancreatic β-cells. The mechanism of action is associated with the ability to block ATP-dependent channels in β-cell membranes by acting on specific receptors, which leads to cell depolarization and the opening of calcium channels. As a result, increased calcium influx induces insulin secretion by β-cells.

After taking repaglinide, an insulinotropic response to food intake is observed within 30 minutes, which leads to a decrease in blood glucose levels. In the periods between meals, there is no increase in insulin concentration. In patients with type 2 diabetes mellitus (non-insulin dependent), when taking repaglinide in doses from 500 mcg to 4 mg, a dose-dependent decrease in blood glucose levels is noted.

Indications

Type 2 diabetes mellitus (with the ineffectiveness of diet therapy, weight loss and physical activity) in monotherapy or in combination with metformin or thiazolidinediones in cases where satisfactory glycemic control cannot be achieved with monotherapy with repaglinide, metformin or thiazolidinediones.

Dosage and administration

inside.Used as an adjunct to diet and exercise to lower blood glucose levels. The dosing regimen is set individually, selecting the dose in order to optimize the glucose level.

The recommended initial daily dose is 0.5 mg. The average daily dose is 12 mg. The maximum daily dose is 16 mg.

Contraindications

Hypersensitivity to repaglinide; type 1 diabetes mellitus, diabetic ketoacidosis, diabetic precoma and coma; infectious diseases, major surgery and other conditions requiring insulin therapy; severe liver dysfunction; concomitant use of gemfibrozil; pregnancy, breastfeeding period; under 18 years of age and over 75 years of age.

With caution: with mild to moderate liver dysfunction, febrile syndrome, chronic renal failure, alcoholism, general serious condition, malnutrition.

Warnings and precautions:

Side effects

From the immune system: very rarely — generalized hypersensitivity reactions; frequency unknown — itching, skin rash, urticaria.

From the side of metabolism: often — hypoglycemia; frequency unknown — hypoglycemic coma, hypoglycemia with loss of consciousness.

On the part of the organ of vision: very rarely — visual impairment, especially at the initial stage of therapy (usually transient).

Storage

Store at a temperature not exceeding 25°C.

Package:

The carton box contains 30 tablets, paper leaflet.